Position in SABS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$17,165,850
+$308,105 QoQ
Shares Held
4,401,500
0.0% QoQ
Ownership
4.84%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#5
of 86 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SABS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. SABS ranks #65 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
10,281,496 | $2,742,280,613 | |
| 2 | PBLS |
Parabilis Medicines, Inc.
|
28,933,371 | $791,906,364 | |
| 3 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
6,666,837 | $740,218,912 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
11,474,599 | $667,018,439 | |
| 5 | SION |
Sionna Therapeutics, Inc.
|
9,905,045 | $435,722,929 | |
| 6 | TYRA |
Tyra Biosciences, Inc.
|
12,198,625 | $389,624,082 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
8,392,730 | $340,996,619 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
9,883,524 | $330,779,298 |
All Filings in SABS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-08-06 | $36,997,930 | 9,609,852 | Shares | Sole | 2026-08-10 | |
| 2026-06-30 | $17,165,850 | 4,401,500 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $16,857,745 | 4,401,500 | Shares | Sole | 2026-05-15 | |
| 2026-03-09 | $19,839,068 | 5,166,424 | Shares | Sole | 2026-03-11 | |
| 2025-12-31 | $16,461,610 | 4,401,500 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,847,015 | 4,401,500 | Shares | Sole | 2025-11-14 | |
| 2025-09-26 | $8,847,015 | 4,401,500 | Shares | Sole | 2025-10-03 | |
| 2023-12-31 | $1,633,367 | 2,374,081 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||